This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck & Co., Inc.

Drug Names(s): Desloratadine, Aerius, Neoclarityn, Azomyr, Aerinaze (desloratadine/pseudoephedrine), MK-4117

Description: Clarinex (Desloratadine) is the second generation of Claritin (Loratadine). Desloratadine is the most active metabolite of loratadine; indeed, it is 14-17 times more potent than its predecessor.

Clarinex (desloratadine) is a long-acting tricyclic anti-histamine with selective H-1 receptor (H1R) histamine antagonist activity. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, bronchoconstriction, increases vascular permeability, potentiates pain, and more.

Deal Structure: Desloratadine was originally developed by Sepracor.

Schering-Plough and Sepracor
In December 1997, Schering-Plough and Sepracor announced a licensing agreement giving Schering-Plough exclusive worldwide rights to Sepracor's patents relating to desloratadine. Sepracor will receive royalties upon launch of CLARINEX in the U.S.

Merck and Schering-Plough
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company.

Dainippon Sumitomo Pharma and Sepracor
In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into...See full deal structure in Biomedtracker

Partners: Sumitomo Dainippon Pharma Co., Ltd. Kyorin Pharmaceutical Co., Ltd. DRI Capital Inc.

Clarinex News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug